Cargando…
Targeting metabolic disorders by natural products
The most prevalent metabolic disorders are diabetes mellitus, obesity, dyslipidemia, osteoporosis and metabolic syndrome, which are developed when normal metabolic processes are disturbed. The most common pathophysiologies of the above disorders are oxidative stress, Nrf2 pathways, epigenetic, and c...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4495701/ https://www.ncbi.nlm.nih.gov/pubmed/26157708 http://dx.doi.org/10.1186/s40200-015-0184-8 |
_version_ | 1782380294072958976 |
---|---|
author | Tabatabaei-Malazy, Ozra Larijani, Bagher Abdollahi, Mohammad |
author_facet | Tabatabaei-Malazy, Ozra Larijani, Bagher Abdollahi, Mohammad |
author_sort | Tabatabaei-Malazy, Ozra |
collection | PubMed |
description | The most prevalent metabolic disorders are diabetes mellitus, obesity, dyslipidemia, osteoporosis and metabolic syndrome, which are developed when normal metabolic processes are disturbed. The most common pathophysiologies of the above disorders are oxidative stress, Nrf2 pathways, epigenetic, and change in miRNA expression. There is a challenge in the prevention and treatment of metabolic disorders due to severe adverse effects of some synthetic drugs, their high cost, lack of safety and poverty in some conditions, and insufficient accessibility for the general population in the world. With increasing interest in shifting from synthetic drugs to phytotherapy as an alternative treatment, there is still a gap in scientific evidences of plant-derived therapeutic benefits. One reason may be slow rate of translation of animal studies’ findings into human clinical trials. Since metabolic disorders are multifactorial, it seems that poly-herbal medications, or drug-herbal combination are needed for their treatment. However, further researches to determine the most effective plant-derived metabolites, and their cellular mechanism in order to set priorities for well-designed animal and clinical trials, and also more studies with strong scientific evidences such as systematic review and meta-analysis of controlled studies are needed. |
format | Online Article Text |
id | pubmed-4495701 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-44957012015-07-09 Targeting metabolic disorders by natural products Tabatabaei-Malazy, Ozra Larijani, Bagher Abdollahi, Mohammad J Diabetes Metab Disord Review The most prevalent metabolic disorders are diabetes mellitus, obesity, dyslipidemia, osteoporosis and metabolic syndrome, which are developed when normal metabolic processes are disturbed. The most common pathophysiologies of the above disorders are oxidative stress, Nrf2 pathways, epigenetic, and change in miRNA expression. There is a challenge in the prevention and treatment of metabolic disorders due to severe adverse effects of some synthetic drugs, their high cost, lack of safety and poverty in some conditions, and insufficient accessibility for the general population in the world. With increasing interest in shifting from synthetic drugs to phytotherapy as an alternative treatment, there is still a gap in scientific evidences of plant-derived therapeutic benefits. One reason may be slow rate of translation of animal studies’ findings into human clinical trials. Since metabolic disorders are multifactorial, it seems that poly-herbal medications, or drug-herbal combination are needed for their treatment. However, further researches to determine the most effective plant-derived metabolites, and their cellular mechanism in order to set priorities for well-designed animal and clinical trials, and also more studies with strong scientific evidences such as systematic review and meta-analysis of controlled studies are needed. BioMed Central 2015-07-08 /pmc/articles/PMC4495701/ /pubmed/26157708 http://dx.doi.org/10.1186/s40200-015-0184-8 Text en © Tabatabaei-Malazy et al. 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Review Tabatabaei-Malazy, Ozra Larijani, Bagher Abdollahi, Mohammad Targeting metabolic disorders by natural products |
title | Targeting metabolic disorders by natural products |
title_full | Targeting metabolic disorders by natural products |
title_fullStr | Targeting metabolic disorders by natural products |
title_full_unstemmed | Targeting metabolic disorders by natural products |
title_short | Targeting metabolic disorders by natural products |
title_sort | targeting metabolic disorders by natural products |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4495701/ https://www.ncbi.nlm.nih.gov/pubmed/26157708 http://dx.doi.org/10.1186/s40200-015-0184-8 |
work_keys_str_mv | AT tabatabaeimalazyozra targetingmetabolicdisordersbynaturalproducts AT larijanibagher targetingmetabolicdisordersbynaturalproducts AT abdollahimohammad targetingmetabolicdisordersbynaturalproducts |